LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Listă Acțiuni・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Închisă

SectorSănătate

54.89 0.96

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

54.31

Maxim

55.05

Indicatori cheie
By Trading Economics
Venit	1.6B 2.7B
Vânzări	-1B 11B
P/E Medie Sector	15.392 49.888
EPS	1.31
Randament dividend	4.37
Marjă de profit	23.309
Angajați	32,500
EBITDA	1.5B 3.7B

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+16.25% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	4.37% 2.38%
Următoarele câștiguri	30 iul. 2026
Data viitoare de dividende	31 iul. 2026
Următoarea dată ex-dividende	2 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-5.8B 112B
Deschiderea anterioară	53.93
Închiderea anterioară	54.89

Sentimentul știrilor

By Acuity

43%

57%

132 / 344 Clasament în Healthcare

Bristol-Myers Squibb Co. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 iun. 2026, 13:08 UTC

Câștiguri

Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial

12 mai 2026, 06:42 UTC

Principalele dinamici ale pieței

Bristol Myers Squibb and China's Hengrui Pharma Forge Tie-Up

30 apr. 2026, 11:14 UTC

Câștiguri

Bristol Myers Squibb Logs Higher 1Q Sales Driven by Growth Portfolio

29 mai 2026, 08:15 UTC

Market Talk

Câștiguri

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

5 mai 2026, 18:12 UTC

Câștiguri

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 mai 2026, 13:54 UTC

Câștiguri

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb: Continue to See Total Worldwide Eliquis Revenue Increasing 10%-15% in 2026 Vs Yr-Ago >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb: 2026 Guidance Excludes Impact of Any Potential Future Strategic Acquisitions, Divestitures and Impact of Future Acquired IPRD Charges and Licensing Income >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb: Reaffirming 2026 Financial Guidance With Total Revenue and Diluted EPS Trending Toward Upper End of Ranges >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb Backs 2026 Rev $46B-$47.5B >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q International Revenue Rose 11% to $3.7B >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb: 1Q Results Reflecting Sustained Momentum Across Our Growth Portfolio and Disciplined Execution Throughout the Business >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q U.S. Revenue Fell 1% to $7.79B >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q Rev $11.49B >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 1Q, Which Was More Than Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb: 1Q Growth Portfolio Revenue Increase Primarily Driven by Reblozyl, Camzyos and Breyanzi >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q Eliquis Revenue Rose 16% to $4.14B >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb Backs 2026 Adj EPS $6.05-Adj EPS $6.35 >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q Adjusted Gross Margin 70.3% >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 12% to $6.23B >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q EPS $1.31 >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 6% to $5.28B >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q Adj EPS $1.58 >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb: Latest 1Q Includes Net Impact of Loss of 3c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30 apr. 2026, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q Gross Margin 70.2% >BMY

14 apr. 2026, 14:13 UTC

Câștiguri

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr. 2026, 12:57 UTC

Câștiguri

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr. 2026, 11:19 UTC

Câștiguri

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 apr. 2026, 10:34 UTC

Câștiguri

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

13 apr. 2026, 21:23 UTC

Câștiguri

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

Comparație

Modificare preț

Bristol-Myers Squibb Co. Așteptări

Obiectiv de preț

By TipRanks

16.25% sus

Prognoză pe 12 luni

Medie 63.31 USD 16.25%

Maxim 75 USD

Minim 40 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBristol-Myers Squibb Co. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

20 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 20 analiști care au acordat evaluări ale acțiunilor Bristol-Myers Squibb Co. - Dist în ultimele 3 luni.

Sentiment

By Acuity

132 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.